On the other hand, an immune checkpoint inhibitor (ICI) has attracted great interest as a new treatment strategy for lung cancer patients and has been approved in EGFR‐TKI‐resistant NSCLC patients. This evidence concerns the gene EGFR and lung carcinoma.